{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:50:24Z","timestamp":1787028624154,"version":"build-2736575974"},"reference-count":33,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2022,1,15]],"date-time":"2022-01-15T00:00:00Z","timestamp":1642204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Bayer, Grifols, Insmed Inc., InfectoPharm, the German Ministry of Research and Education (BMBF), German Center for Lung Research (DZL), German Center for Infection Research (DZIF), EMBARC\/IMI\/EFPIA project iABC (grant 115721)","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Patients with bronchiectasis feature considerable symptom burden and reduced health-related quality of life (QOL). We provide the psychometric validation of the German translation of the disease-specific Quality of Life Questionnaire-Bronchiectasis (QOL-B), version 3.1, using baseline data of adults consecutively enrolled into the prospective German bronchiectasis registry PROGNOSIS. Overall, 904 patients with evaluable QOL-B scores were included. We observed no relevant floor or ceiling effects. Internal consistency was good to excellent (Cronbach\u2019s \u03b1 \u22650.73 for each scale). QOL-B scales discriminated between patients based on prior pulmonary exacerbations and hospitalizations, breathlessness, bronchiectasis severity index, lung function, sputum volume, Pseudomonas aeruginosa status and the need for regular pharmacotherapy, except for Social Functioning, Vitality and Emotional Functioning scales. We observed moderate to strong convergence between several measures of disease severity and QOL-B scales, except for Social and Emotional Functioning. Two-week test-retest reliability was good, with intraclass correlation coefficients \u22650.84 for each scale. Minimal clinical important difference ranged between 8.5 for the Respiratory Symptoms and 14.1 points for the Social Functioning scale. Overall, the German translation of the QOL-B, version 3.1, has good validity and test-retest reliability among a nationally representative adult bronchiectasis cohort. However, responsiveness of QOL-B scales require further investigation during registry follow-up.<\/jats:p>","DOI":"10.3390\/jcm11020441","type":"journal-article","created":{"date-parts":[[2022,1,16]],"date-time":"2022-01-16T20:44:00Z","timestamp":1642365840000},"page":"441","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Psychometric Validation of the German Translation of the Quality of Life Questionnaire-Bronchiectasis (QOL-B)\u2014Data from the German Bronchiectasis Registry PROGNOSIS"],"prefix":"10.3390","volume":"11","author":[{"given":"Laura","family":"Quellhorst","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Hannover Medical School (MHH), 30625 Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grit","family":"Barten-Neiner","sequence":"additional","affiliation":[{"name":"CAPNETZ STIFTUNG, Hannover Medical School (MHH), 30625 Hannover, Germany"},{"name":"Biomedical Research in End-Stage and Obstructive Lung Disease Hannover (BREATH), German Center for Lung Research (DZL), 30625 Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"de Roux","sequence":"additional","affiliation":[{"name":"Pneumologische Praxis am Schloss Charlottenburg, 14059 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Diel","sequence":"additional","affiliation":[{"name":"Institute for Epidemiology, University Medical Center Schleswig-Holstein, 24105 Kiel, Germany"},{"name":"LungenClinic Grosshansdorf, Airway Research Center North (ARCN), German Center for Lung Research (DZL), 22927 Grosshansdorf, Germany"},{"name":"Institution for Statutory Accident Insurance and Prevention in the Health and Welfare Services (BGW), 22089 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pontus","family":"Mertsch","sequence":"additional","affiliation":[{"name":"Department of Medicine V, University Hospital, LMU Munich, Comprehensive Pneumology Center Munich (CPC-M), German Center for Lung Research (DZL), 81377 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabell","family":"Pink","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Hannover Medical School (MHH), 30625 Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Rademacher","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Hannover Medical School (MHH), 30625 Hannover, Germany"},{"name":"Biomedical Research in End-Stage and Obstructive Lung Disease Hannover (BREATH), German Center for Lung Research (DZL), 30625 Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sivagurunathan","family":"Sutharsan","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, University Hospital Essen, Ruhrlandklinik, University Duisburg-Essen, 45239 Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Welte","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Hannover Medical School (MHH), 30625 Hannover, Germany"},{"name":"Biomedical Research in End-Stage and Obstructive Lung Disease Hannover (BREATH), German Center for Lung Research (DZL), 30625 Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annegret","family":"Zurawski","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Hannover Medical School (MHH), 30625 Hannover, Germany"},{"name":"Biomedical Research in End-Stage and Obstructive Lung Disease Hannover (BREATH), German Center for Lung Research (DZL), 30625 Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9084-4968","authenticated-orcid":false,"given":"Felix C.","family":"Ringshausen","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Hannover Medical School (MHH), 30625 Hannover, Germany"},{"name":"Biomedical Research in End-Stage and Obstructive Lung Disease Hannover (BREATH), German Center for Lung Research (DZL), 30625 Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the PROGNOSIS study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,1,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Aliberti, S., Goeminne, P.C., O\u2019Donnell, A.E., Aksamit, T.R., Al-Jahdali, H., Barker, A.F., Blasi, F., Boersma, W.G., Crichton, M.L., and De Soyza, A. (Lancet Respir. Med., 2021). Criteria and definitions for the radiological and clinical diagnosis of bronchiectasis in adults for use in clinical trials: International consensus recommendations, Lancet Respir. Med., Online ahead of print.","DOI":"10.1016\/S2213-2600(21)00277-0"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1183\/13993003.01033-2015","article-title":"Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: A population-based cohort study","volume":"47","author":"Quint","year":"2016","journal-title":"Eur. Respir. J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1900499","DOI":"10.1183\/13993003.00499-2019","article-title":"Increasing bronchiectasis prevalence in Germany, 2009\u20132017: A population-based cohort study","volume":"54","author":"Ringshausen","year":"2019","journal-title":"Eur. Respir. J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1802033","DOI":"10.1183\/13993003.02033-2018","article-title":"Economic burden of bronchiectasis in germany","volume":"53","author":"Diel","year":"2019","journal-title":"Eur. Respir. J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2001451","DOI":"10.1183\/13993003.01451-2020","article-title":"Efficacy and safety of TOBI podhaler in pseudomonas aeruginosa-infected bronchiectasis patients: iBEST study","volume":"57","author":"Loebinger","year":"2021","journal-title":"Eur. Respir. J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S2213-2600(18)30427-2","article-title":"Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): Two phase 3, randomised controlled trials","volume":"7","author":"Haworth","year":"2019","journal-title":"Lancet Respir. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S2213-2600(14)70165-1","article-title":"Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): Two randomised double-blind, placebo-controlled phase 3 trials","volume":"2","author":"Barker","year":"2014","journal-title":"Lancet Respir. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1378\/chest.12-1763","article-title":"Phase 3 randomized study of the efficacy and safety of inhaled dry powder mannitol for the symptomatic treatment of non-cystic fibrosis bronchiectasis","volume":"144","author":"Bilton","year":"2013","journal-title":"Chest"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1183\/13993003.01888-2015","article-title":"Research priorities in bronchiectasis: A consensus statement from the EMBARC clinical research collaboration","volume":"48","author":"Aliberti","year":"2016","journal-title":"Eur. Respir. J."},{"key":"ref_10","unstructured":"U.S. Food & Drug Administration (FDA) (2021, November 20). Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims, Available online: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-reported-outcome-measures-use-medical-product-development-support-labeling-claims."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.chest.2020.08.2055","article-title":"Development of drugs for nontuberculous mycobacterial disease: Clinicians\u2019 interpretation of a US Food and Drug Administration workshop","volume":"159","author":"Flume","year":"2021","journal-title":"Chest"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/thoraxjnl-2014-205918","article-title":"Quality of life questionnaire-bronchiectasis: Final psychometric analyses and determination of minimal important difference scores","volume":"70","author":"Quittner","year":"2015","journal-title":"Thorax"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1136\/thoraxjnl-2015-207315","article-title":"The validity of health-related quality of life questionnaires in bronchiectasis: A systematic review and meta-analysis","volume":"71","author":"Spinou","year":"2016","journal-title":"Thorax"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1601532","DOI":"10.1183\/13993003.01532-2016","article-title":"The development and validation of the Bronchiectasis Health Questionnaire","volume":"49","author":"Spinou","year":"2017","journal-title":"Eur. Respir. J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2003156","DOI":"10.1183\/13993003.03156-2020","article-title":"Validation of the Bronchiectasis Impact Measure (BIM): A novel patient-reported outcome measure","volume":"57","author":"Crichton","year":"2021","journal-title":"Eur. Respir. J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2100025","DOI":"10.1183\/13993003.00025-2021","article-title":"Psychometrics of health-related quality of life questionnaires in bronchiectasis: A systematic review and meta-analysis","volume":"58","author":"McLeese","year":"2021","journal-title":"Eur. Respir. J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1164\/rccm.201309-1575OC","article-title":"The Bronchiectasis Severity Index. An international derivation and validation study","volume":"189","author":"Chalmers","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1007\/s11136-013-0560-0","article-title":"Validation of a quality of life questionnaire for bronchiectasis: Psychometric analyses of the Spanish QOL-B-V3.0","volume":"23","author":"Olveira","year":"2014","journal-title":"Qual. Life Res."},{"key":"ref_19","first-page":"391","article-title":"[PROGNOSIS\u2014The prospective German non-cf bronchiectasis patient registry]","volume":"69","author":"Rademacher","year":"2015","journal-title":"Pneumologie"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2214\/ajr.165.2.7618537","article-title":"CT findings in bronchiectasis: Limited value in distinguishing between idiopathic and specific types","volume":"165","author":"Reiff","year":"1995","journal-title":"AJR Am. J. Roentgenol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1378\/chest.13-1891","article-title":"A preliminary quality of life questionnaire-bronchiectasis: A patient-reported outcome measure for bronchiectasis","volume":"146","author":"Quittner","year":"2014","journal-title":"Chest"},{"key":"ref_22","unstructured":"Field, A. (2009). Correlation. Discovering Statistics Using SPSS, SAGE Publications Ltd.. [3rd ed.]."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/crj.12198","article-title":"Validation of a visual analogue score (LRTI-VAS) in non-CF bronchiectasis","volume":"10","author":"Altenburg","year":"2016","journal-title":"Clin. Respir. J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.chest.2019.10.030","article-title":"Validation of the COPD Assessment Test (CAT) as an outcome measure in bronchiectasis","volume":"157","author":"Finch","year":"2020","journal-title":"Chest"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1183\/09031936.00160508","article-title":"Validation of the Leicester Cough Questionnaire in non-cystic fibrosis bronchiectasis","volume":"34","author":"Murray","year":"2009","journal-title":"Eur. Respir. J."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2000110","DOI":"10.1183\/13993003.00110-2020","article-title":"Changes in respiratory symptoms during 48-week treatment with ARD-3150 (inhaled liposomal ciprofloxacin) in bronchiectasis: Results from the ORBIT-3 and -4 studies","volume":"56","author":"Chalmers","year":"2020","journal-title":"Eur. Respir. J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2000608","DOI":"10.1183\/13993003.00608-2020","article-title":"Inhaled aztreonam improves symptoms of cough and sputum production in patients with bronchiectasis: A post hoc analysis of the AIR-BX studies","volume":"56","author":"Crichton","year":"2020","journal-title":"Eur. Respir. J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1702053","DOI":"10.1183\/13993003.02053-2017","article-title":"RESPIRE 2: A phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis","volume":"51","author":"Aksamit","year":"2018","journal-title":"Eur. Respir. J."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1702052","DOI":"10.1183\/13993003.02053-2017","article-title":"RESPIRE 1: A phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis","volume":"51","author":"Aksamit","year":"2018","journal-title":"Eur. Respir. J."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1136\/thoraxjnl-2013-203207","article-title":"Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): A randomised, double-blind, placebo-controlled trial","volume":"68","author":"Serisier","year":"2013","journal-title":"Thorax"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1001\/jama.2013.2290","article-title":"Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: The BLESS randomized controlled trial","volume":"309","author":"Serisier","year":"2013","journal-title":"JAMA"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jclinepi.2007.03.012","article-title":"Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes","volume":"61","author":"Revicki","year":"2008","journal-title":"J. Clin. Epidemiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e1269","DOI":"10.1016\/S2214-109X(19)30327-4","article-title":"Bronchiectasis in India: Results from the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) and Respiratory Research Network of India Registry","volume":"7","author":"Dhar","year":"2019","journal-title":"Lancet Glob. Health"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/2\/441\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:27:30Z","timestamp":1760362050000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/2\/441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,15]]},"references-count":33,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,1]]}},"alternative-id":["jcm11020441"],"URL":"https:\/\/doi.org\/10.3390\/jcm11020441","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,15]]}}}